Across TCGA pan-cancer cohorts, EXOC5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EXOC5 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher EXOC5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EXOC5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
ESCA, UCEC, and OV are the cancer types where EXOC5 Mutation most reproducibly stratifies survival.